drugset / Trial / NCT03433040
17OHP-C Dosing Among Obese Pregnant Women
Phase 3
Completed
44 enrolled
University of South Florida
Washington University School of Medicine · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Emergency data suggest 17OHP-C may be less efficacious in obese women. Since obesity is associated with lower levels of plasma 17OHP-C, the investigator hypothesize that higher doses of 17OHP-C may help to prevent spontaneous PTB among obese women. The study aims to compare the pharmacokinetics of 17 OHP-C in obese compared with non-obese women.
Timeline
- Start
- 2017-08-23
- Primary completion
- 2021-06-01
- Completion
- 2021-07-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 17-Hydroxyprogesterone Capronate | Unknown | 250 mg | — |
| Subject | 17-Hydroxyprogesterone Capronate | Unknown | 500 mg | — |
Indications
No indication recorded.